Current evidence between hospital volume and perioperative outcome: Prospective assessment of robotic radical prostatectomy safety profile in a regional center of medium annual caseload

Matteo Ferrari, MD¹; Brunello Mazzola, MD¹; Enrico Roggero, MD²; Eugenia D'Antonio, MD²; Ricardo Pereira Mestre, MD²; Giovanni Porcu, MD¹; Flavio Stoffel, MD¹; Julien Renard, MD^{1,3}

¹Division of Urology, Bellinzona Regional Hospital, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; ²Clinic of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; ³Division of Urology, Geneva University Hospitals, Geneva, Switzerland

Cite as: Ferrari M, Mazzola B, Roggero E, et al. Current evidence between hospital volume and perioperative outcome: Prospective assessment of robotic radical prostatectomy safety profile in a regional center of medium annual caseload. *Can Urol Assoc J* 2021;15(3):E153-9. http://dx.doi. org/10.5489/cuaj.6547

Published online August 7, 2020

Abstract

Introduction: We aimed to present the safety profile of robotic radical prostatectomy (RARP) performed in a single center of medium surgical volume since its introduction and identify predictors of postoperative complications.

Methods: We prospectively collected clinical data from 317 consecutive patients undergoing RARP between August 2011 and November 2019 in a medium-volume center. Surgical procedures were performed by a single experienced surgeon. Complications were collected according to the Martin criteria for reporting and the Clavien-Dindo classification for rating. Preoperative, intraoperative, and postoperative data were analyzed and compared with available literature.

Results: A total of 102 complications were observed in 96 (30.3%) patients and were minor in 84.4% of cases (Clavien grade 1 and 2). Transfusion rate was 1.3%. Complications of grade 4b or 5 did not occur. The most frequent complications were urinary retention (7.3%) and anastomotic leak (5.9%). At multivariate analysis, the nerve-sparing technique was an independent predictor of complications (odds ratio [OR] 0.55, p=0.02).

Conclusions: The study shows that a high safety profile may be achieved in a medium-volume hospital. The nerve-sparing technique was a predictor of complications. Further studies are needed to define the current relationship between surgical volume and perioperative outcome for RARP.

Introduction

Robotic surgery was developed to overcome problems faced during conventional laparoscopic surgeries and represents today the epitome of minimally invasive surgery. Since its introduction in urology, robot-assisted surgery has shown great technical advantages in the execution of radical prostatectomy (RP), becoming today the reference surgical approach for the treatment of localized prostate cancer (PCa). The diffusion of the robot-assisted radical prostatectomy (RARP) technique has grown at the same time, as many studies showing surgical robotic outcomes comparable to the conventional open surgical results with lower perioperative complications rates.^{1,2} However, in RP series performed with robotic procedure, the association between high-volume surgery and improved surgical outcome has proved to be particularly solid.^{3,4}

This data can be interpreted by the fact that compared to conventional open techniques, RARP is a complex technical procedure presenting many potential risks of intra- or postoperative complications and requiring a long learning curve for the surgeon, with initially lower-level outcomes.⁵ In this context, scientific evidence supporting the use of the RARP technique are mainly based on studies from high-volume centers; however, due to the geographical diffusion of this technology, many patients are treated in centers of lowervolume. The safety and quality level of RARP procedure in smaller hospitals, therefore, no longer represents a negligible theme in the field of public health.

The aim of the present study is to objectively assess, using a standardized and validated reporting methodology,⁶ perioperative complications of the RARP technique in a European center of medium surgical volume. The secondary endpoint is to identify pre- and intraoperative predictors of surgical complications.

Methods

Patient population

The prospective study includes clinical data of 317 consecutive patients undergoing RARP between August 2011, the start date of the robotic program at San Giovanni Regional Hospital (Bellinzona, Switzerland), and November 2019. Data collection was done following the principles outlined in the Declaration of Helsinki and after institutional review board approval.

Before surgery, all patients were assessed thorough physical examination, including body mass index (BMI, defined as weight in kg by height in m²), and detailed medical interview, including chronic pharmacological therapy (in particular, antiplatelet or anticoagulant drugs) and smoking. Health-significant comorbidities were scored using the American Society Anesthesiologists (ASA) and the Charlson Comorbidity Index (CCI) scores.

Surgical technique

Surgical procedures were performed by a single surgeon (BM) trained in robotic surgery using the da Vinci Si System[®] (Intuitive Surgical Inc. Sunnyvale, CA, U.S.) through a transperitoneal access, according to Menon technique.⁷

Thirty minutes before the start of surgical procedure, all patients received parenteral administration of antibiotic prophylaxis with a broad-spectrum, third-generation cephalosporin. Postoperative antibiotic therapy (oral quinolone) was continued until discharge. Bilateral extended pelvic lymphadenectomy was performed according to the preoperative risk assessment.⁸ In all patients, para-anastomotic drainage was not placed. Anti-thrombotic prophylaxis with low molecular weight heparin was administered until discharge.

In agreement with our clinical practice, the bladder catheter was removed on the sixth postoperative day; cystography control was performed in all patients before catheter retrieval. Patients were discharged 24 hours after catheter removal.

Data analysis

Dedicated pathologists processed and examined the preparations in accordance with the ISUP protocol for RP.⁹ Surgical complications were reported satisfying all 10 Martin criteria¹⁰ for their description. The Clavien-Dindo system¹¹ was used to classify the severity of individual complications.

Statistical analysis

Quantitative data were summarized as mean with the corresponding standard deviation (SD) or as median with the corresponding interquartile range (IQR) as appropriate. Qualitative data were presented as absolute numbers with percentages. To analyze the association between surgical time, blood loss, and date of surgery, the Pearson correlation coefficient was used. To identify potential predictors of postoperative complications, we first performed a univariate logistic regression followed by a multivariable logistic regression model. All tests were two-sided and p<0.05 was considered statistically significant. All statistical analyses were performed with Stata version 15 (StataCorp LP, College Station, TX, U.S.)

Results

Table 1 shows preoperative clinical characteristics of patients. Table 2 show perioperative surgical data. The duration of surgery significantly decreased throughout the series (correlation coefficient=-0.66, coefficient of determination (R^2)=0.43, p=0.00) (Fig. 1). Intraoperative blood losses remained constant (correlation coefficient=0.002, R^2 =0.0001, p=0.89) (Fig. 2).

The detailed list of 102 surgical complications is shown in Table 3. The data were collected up to three months after the intervention. Overall, complications occurred in 30.3% (96/317) of patients. Analyzed for severity, most complications were minor: 84.4% of complications were grade 1 or 2. No intraoperative surgical or anesthesiologic complications requiring temporary suspension of procedure occurred. In five cases (5.2%), the complication occurred 30 days after the procedure.

Overall, blood transfusion rate was 1.3%. Bleeding complications occurred in 3.4% (11/317) of patients and account for 10.8% (11/102) of all complications. Active bleeding occurred in two (1.6%) patients: one case of hematuria treated with bladder irrigation (not requiring blood transfusion) and one case of pelvic bleeding requiring open surgical revision. Considering the risk of bleeding, it is of interest to report that antiplatelet or oral anticoagulation therapy was used overall in 16.1% (51/317) of patients. However, of patients requiring blood transfusion, nobody took antiplatelet or oral anticoagulation therapy.

Acute urinary retention at the time of bladder catheter removal was successfully treated with the repositioning of bladder catheter for a further seven days, except for one case (requiring 16 days).

Anastomotic leak was observed in 19 patients. In two cases, complication occurred in the first postoperative day and was managed with placement of bilateral "mono-J" ureteral stent, removed after 7 and 14 days (bladder catheter in place for 22 and 35 days), respectively. The other cases consisted of an anastomotic leak at routine cystogram treated conservatively with an indwelling bladder catheter until a negative cystogram was obtained (median: 32 days postoperatively, range 11–62).

Four patients with symptomatic lymphocele causing lymphedema of the lower limb were treated with compressive stockings and oral anticoagulation therapy; one case was associated with a deep vein thrombosis. Three patients with symptomatic infected lymphocele required percutaneous drainage.

Concerning visceral complications, two patients who underwent extended adhesiolysis during RARP (one with history of diverticulosis and left hemicolectomy) developed peritonitis

 Table 1. Preoperative clinical data of patients undergoing robotic radical prostatectomy (n=317)

robotic radical prostatectomy (n=317)	
Variable	
Age (yrs), mean ± SD	63.3±5.9
$BMI (kg/m^2)$, mean ± SD	26.5±3.5
Prostate volume (cm ³), median(IQR)	37 (29–48)
	57 (25 40)
Clinical stage, n (%) T1b	0 (0.0)
T1c	87 (28.8)
T2a	114 (37.7)
T2b	37 (12.3)
T2c	38 (12.6)
T3	26 (8.6)
T4	0(0.0)
PSA (ng/ml), median (IQR)	10 (7.0–14.7)
D'Amico risk group, n (%)	,
1	34 (11.3)
2	139 (46.3)
3	127 (42.4)
AMI, n (%)	127 (12.17
No	304(95.9)
Yes	13 (4.1)
	13 (4.1)
Smoke, n (%) No	250 (78.9)
Yes	67 (21.1)
	07 (21.1)
COPD, n (%)	000 (00 5)
No Yes	306 (96.5)
	11(3.5)
Hypertension, n (%)	400 (50.0)
No	190 (59.9)
Yes	127 (40.1)
Stroke, n (%)	
No	317 (100.0)
Yes	0 (0.0)
Diabetes, n (%)	
No	282 (89.0)
Yes	35 (11.0)
Immune system disorders, n (%)	
No	304 (95.9)
Yes	13(4.1)
LUTS, n (%)	
No	271 (85.8)
Yes	45 (14.2)
TURP, n (%)	
No	307 (96.8)
Yes	10 (3.2)
Prostatitis, n (%)	
No	285 (89.9)
Yes	32 (10.1)
Bladder surgery, n (%)	
No	315 (99.4)
Yes	2 (0.6)
Abdominal surgery, n (%)	
No	208 (65.6)
Yes	109 (34.4)
AMI: acute myocardial infarction; ASA: American Society of	Anesthesiologists; APT:

AMI: acute myocardial infarction; ASA: American Society of Anesthesiologists; APT: antiplatelet therapy; BMI: body mass index; CCI: Charlson comorbidity index; COPD: chronic obstructive pulmonary disease; IQR: interquartile range; LUTS: lower urinary tract symptoms; NA: not applicable; OAC: oral anticoagulation therapy; PSA: prostate-specific antigen; SD: standard deviation; TURP: transurethral resection of prostate.

Table 1 (cont'd). Preoperative clinical data of patients undergoing robotic radical prostatectomy (n=317)

undergoing robotic radical pro	statectomy (n=517)
Variable	
APT/OAC, n (%)	
No	266 (83.9)
APT	46 (14.5)
OAC	4 (1.3)
APT+OAC	1 (0.3)
ASA, n (%)	
1	81 (25.5)
2	155 (48.9)
3	68 (21.5)
4	13 (4.1)
CCI, n (%)	
0	5 (1.6)
1	51 (16.1)
2	133 (41.9)
3	95 (30.0)
4	26 (8.2)
5	6 (1.9)
7	1 (0.3)

AMI: acute myocardial infarction; ASA: American Society of Anesthesiologists; APT: antiplatelet therapy; BMI: body mass index; CCI: Charlson comorbidity index; COPD: chronic obstructive pulmonary disease; IQR: interquartile range; LUTS: lower urinary tract symptoms; NA: not applicable; OAC: oral anticoagulation therapy; PSA: prostate-specific antigen; SD: standard deviation; TURP: transurethral resection of prostate.

secondary to perforation of the small intestine in the first postoperative day. The patients underwent open surgical revision with bowel resection. A third patient developed obstructive jaundice on a cholelithiasis basis on the third postoperative day and was treated with oral antibiotic therapy. The other patients were suffering from prolonged paralytic ileus, all resolved with gastrointestinal prokinetic agents.

The cases of respiratory complications were secondary to lung atelectasis associated to monolateral pleural effusion and treated with oral antibiotic therapy and respiratory physiotherapy.

Neurological damage was reported in five patients with transient monolateral deficiency of obturator nerve, all spontaneously resolving within 60 days.

Classifying complications based on the infectious nature, documented or suspected, 21 patients (6.6%) were affected; these were classified as lower urinary tract infections (n=8), respiratory tract infections (n=2), wound infections (n=2), hyperpyrexia of unknown origin (treated with intravenous broad-spectrum antibiotics, n=5), lymphocele infection (n=3), and balanoposthitis (n=1).

The results of the univariate and multivariate logistic regression analysis are reported in Table 4.

Discussion

The current expansion of RARP technique, linked to several factors, including increased patient demand and market pressure, makes it essential to evaluate the conditions under which the procedure is performed.

 Table 2. Perioperative clinical data of patients undergoing robotic radical prostatectomy (n=317)

Variable	
Operation time (min), mean ± SD	226.8±49.2
PLND, n (%)	
No	36 (11.4)
Yes	281 (88.6)
Blood loss (ml), mean ± SD	328.3±140.6
Hernia repair, n (%)	
No	307 (96.8)
Yes	10 (3.2)
Nerve-sparing, n (%)	
No	89 (37.4)
Monolateral	114 (47.9)
Bilateral	35 (14.7)
Conversion to open surgery, n (%)	
No	317 (100.0)
Yes	0 (0.0)
DaVinci [®] technical defects, n (%)	
No	317 (100.0)
Yes	0 (0.0)
Pathological stage, n (%)	
pT2a	30 (9.5)
pT2b	3 (0.9)
pT2c	135 (42.6)
рТЗа	92 (29.0)
pT3b	57 (18.0)
pT4	0 (0.0)
Gleason sum, n (%)	
3+3	24 (7.6)
3+4	123 (38.8)
4+3	91 (28.7)
4+4	32 (10.1)
3+5	4 (1.2)
4+5	30 (9.5)
5+4 5+5	12 (3.8) 1 (0.3)
	1 (0.3)
Surgical margins, n (%)	220 (72 0)
Negative Positive	230 (72.6)
T2/all T2	87 (27.4) 27/168 (16.1)
T3/all T3	60/149 (40.2)
	00/143 (40.2)
pN+, n (%) No	232 (82.6)
Yes	49 (17.4)
N° of LN removed, mean ± SD	14.3±6.8
Hospital stay (days), median (IQR)	8 (8–9)
Bladder catheter removal (day), median (IQR)	6 (6–6)
IQR: interquartile range; PLND: pelvic lymph node dissection; pN+: standard deviation.	positive node; SD:

In surgery, a measure of quality is represented by the rate of perioperative complications; a factor associated with this outcome is hospital volume.¹² The literature addressing RARP technique is heterogeneous and characterized by studies with different statistical methods and cutoffs to define the effective center volumes. The most extensive studies have been conducted on populations of North America.




Fig. 1. Operating time in minutes (Y-axis) over the years of study (X-axis), 95% confidence interval (correlation coefficient=-0.66, R^2 =0.43, p=0.00).

Using the Nationwide Inpatient Sample (NIS) database, Trinh et al¹³ identified 11 889 patients who underwent RARP between 2008 and 2009 in centers with a median annual hospital volume of 121 (range 66–184) cases, finding a total postoperative complication rate of 8.2% and a transfusion rate of 2.0%.

Using the same database, Yu et al³ analyzed complications in 2348 RARP performed in the last quarter of 2008. The authors divided the centers of origin into low- (1–15), medium- (16–29), high- (30–54), and very high- (55–166) volume, finding a significant difference (p<0.01) in surgical complications rate (11.2%, 7.6%, 6.7%, and 6.9%, respectively). Defining the center of the present study through these categories, it would be of high-volume but with a much higher complication rate.

Transfusion rate in low-volume hospitals was 2.4% vs. 2.3%, 1.0%, and 0.7% in medium-, high- and very high-volume centers, respectively (p=0.06). In the present study, the transfusion rate was 1.3%, which stands in the range between a center of medium- and high-volume. Liu et al¹⁴ analyzed clinical data of 4036 laparoscopic and robotic prostatectomies performed from 2005–2010 and included in the National Surgical Quality Improvement Program Database (NSQIP). The data refer to centers defined at high-volume (cutoff not shown). The overall 30-day postoperative complication rate was 5%, with mortality of 0.05%. Transfusion rate was 1.3%, comparable to our hospital.

The low complication rate shown in the North American studies described above may be the result of several methodological factors. In fact, using the NIS database registration of postoperative complications is limited to those occurring during hospital stay;^{3,13} moreover, short duration of hospital stay may represent an additional factor in reducing documented complications. Second, only complications predictive of mortality, such as severe complications or blood transfusions, are identified. Lastly, in the case of the NSQIP database, the comparison is limited by the fact that the results derive not only from robotic but also laparoscopic procedures.




Fig. 2. Intraoperative blood loss in milliliters (Y-axis) over the years of study (X-axis), 95% confidence interval (correlation coefficient=0.002, R²=0.0001, p=0.89).

If we consider with the same methodology as described above the grade 3 complications that occurred in the present study (grades 4 or 5 did not occur), the rate would be 4.7%, similar to that of high-volume centers described in the North American databases. In this context, series derived from individual centers generally provide more details and use more standardized data collection methods.

In a study conducted according to all 10 Martin criteria in a high-volume hospital (103 patients/year, University of Padua), Novara et al¹⁵ reported a total complication rate of 22%, with 3% being grade 3 and 4. These results are similar to those reported in the present study. The most frequent complications described were bleeding (5.3%), lymphorrhea (4.3%), and hematoma (2.4%).

Two other studies performed in high-volume centers, the Florida Hospital Celebration Health¹⁶ and the Vattikuti Urology Institute,¹⁷ conducted respecting nine of Martin's criteria, reported much lower rates: an overall complication rate of 5% and 9.8% and a transfusion rate of 0.5% and 2.2%, respectively.

Other European studies reported in the literature were conducted according to the Clavien-Dindo classification and Martin criteria; their results were comparable with the results of the present study.

The surgical volume estimated in these studies is heterogeneous and ranges from 21–250 patients per year.¹⁸⁻²⁴ Major complications occurred rarely and generally in the same frequency in all centers (3–7%). Blood transfusion rates ranged from 1–5%. Overall complications rates, including minor events, are highly variable (6–28%), indicating a heterogeneous method of collection. A clear relationship between volume and surgical outcome did not emerge from these studies.

Two of these studies were conducted in medium- (50 cases per year)²⁴ and high-volume (105 cases per year)²¹ centers in the same country as our hospital. Our overall and major complication rates are similar to the hospital of greater volume (28% and 3%, respectively).

The aforementioned studies investigated the relationship

 Table 3. Postoperative surgical complications of patients undergoing robotic radical prostatectomy (n=317)

undergoing robotic radical prostatectomy (n	=317)
Variable	
Patients affected by complications, n (%)	
No	221 (69.7)
Yes	96 (30.3)
	00 (00.0)
Complications (day of onset), n (%)	01 (01 0)
<30	91 (94.8)
30–90	5 (5.2)
>90	0 (0.0)
Clavien grade, n (%)*§	
1	53 (55.2)
11	28 (29.2)
Illa	7 (7.3)
IIIb	8 (8.3)
IVa	0 (0.0)
IVb	0 (0.0)
Blood transfusion, n (%)	- ()
No	313 (98.7)
Yes	4 (1.3)
Pulmonary complications, n (%)	
No	315 (99.4)
Yes	2 (0.6)
Visceral complications, n (%)	
No	300 (94.6)
Yes	17 (5.4)
Cardiovascular complications, n (%) No	216 (00 7)
	316 (99.7)
Yes	1 (0.3)
Neurologic complications, n (%)	
No	312 (98.4)
Yes	5 (1.6)
DVT, n (%)	
No	314(99.1)
Yes	3 (0.9)
Wound infections, n (%)	
No	315 (99.4)
Yes	
	2 (0.6)
Acute urinary retention, n (%)	
No	294 (92.7)
Yes	23 (7.3)
Anastomotic leak, n (%)	
No	298 (94.1)
Yes	19 (5.9)
Genital/LUT infections, n (%)	
No	309 (97.5)
Yes	8 (2.5)
	0 (2.5)
Pelvic/scrotal/abdominal wall hematoma, n (%)	
No	308 (97.2)
Yes	9 (2.8)
Symptomatic lymphocele, n (%)	
No	310 (97.8)
Yes	7 (2.2)
Active bleeding/hematuria, n (%)	,
No	315 (99.4)
Yes	
	2 (0.6)
*Major per patient complication; ^s ≥1 complication per patient. DVT: d	eep venous

*Major per patient complication; ^s≥1 complication per patient. DVT: deep venous thrombosis; LUT: lower urinary tract.

Variable	Univariable logistic regression			Multivariable logistic regression		
	OR	95% CI	р	OR	95% CI	р
Age (yrs)	1.01	0.96-1.06	0.57	0.96	0.89–1.05	0.43
BMI (kg/m ²)	1.00	0.90-1.11	0.92	-	-	-
Prostate volume (cm ³)	1.00	0.98-1.02	0.70	-	-	-
Clinical stage	0.95	0.72-1.24	0.72	-	-	-
PSA (ng/ml)	1.01	0.98-1.05	0.29	-	-	-
D'Amico risk group	1.25	0.72-2.16	0.41	-	-	-
ASA score	1.27	0.71-2.27	0.41	-	-	-
CCI score	1.32	0.88–1.97	0.16	1.45	0.75-2.80	0.26
APT/OAC	1.58	0.71–3.53	0.25	-	-	-
Diabetes	0.68	0.23-1.97	0.48	-	-	-
COPD	1.27	0.41-3.92	0.67	-	-	-
Smoke	0.84	0.31-2.29	0.74	-	-	-
Operation time	1.00	0.99-1.01	0.53	-	-	-
Blood loss	0.99	0.99-1.00	0.75	-	-	-
PLND	4.31	0.53–34.51	0.17	3.00	0.36-24.72	0.31
Nerve-sparing	0.50	0.31–0.82	0.01	0.55	0.34–0.92	0.02
Associated surgery	1.24	0.47-3.29	0.65	_	-	-

Table 4. Potential pre- and intraoperative risk factors associated with postoperative complications in univariable and multivariable logistic regression analysis

Univariable logistic regression shows bivariate associations without adjustment; multivariable logistic regression results are adjusted for all effects shown. ASA: American Society of Anesthesiologists; APT: antiplatelet therapy; BMI: body mass index; CCI: Charlson comorbidity index; CI: confidence interval; COPD: chronic obstructive pulmonary disease; OAC: oral anticoagulation therapy; OR: odds ratio; PLND: pelvic lymph node dissection.

between perioperative complications and hospital volume, however, another factor to consider should be the surgeon's volume.

Hu et al²⁵ using the data of Center of Medicare and Medicaid Services, analyzed 608 procedures of laparoscopic and RARP in patients over 65 years, performed from 2003–2005. The authors reported an overall complication rate higher than those reported in the present study (29% vs. 22% and 18% in hospital 1 and 2, respectively), not finding any association between surgeon volume (analyzed as variable continuous) and perioperative complications, length of hospital stay, or anastomosis stricture.

Likewise, Budäus et al,²⁶ using data derived from 2666 laparoscopic and robotic prostatectomies performed from 2002–2008 at the Florida Hospital, investigated the relationship between surgical experience and two endpoints: rates of intrahospital complications and blood transfusion.

The surgeon's volume was divided according to the number of annual procedures performed in low- (<16), medium-(16–63), and high-volume (>63). The overall rate of life-threatening complications during hospital stay was 14%, 8%, and 6% for low-, medium-, and high-volume surgeons (p<0.01), respectively. Transfusion rates were 3.5%, 1%, and 0.5%, respectively (p<0.01).

With the present focusing on a single-surgeon, hospital volume coincides with surgeon volume, which corresponds to a medium tertile. According to the Budäus study, blood transfusion rate confirms those of a medium-volume surgeon. Overall complications rates are much higher, likely due to methodological differences: considering only grade 3 complications (4 or 5 did not occur), our surgeon appeared to have similar results to the high-volume surgeons reported by Budäus.

Several studies conducted in patients undergoing radical prostatectomy simultaneously investigated hospital and surgeon volume, and their results suggest that the importance of one or other factor depends on the endpoint of interest.^{25,27,28} Surgeon volume seems to have a significant effect on outcomes directly related to specific surgical maneuvers, while hospital volume seems to influence patient perioperative care.

Positive surgical margin rate is an intraoperative measure of the quality of the procedure and has been shown to be associated with the surgeon's experience. In the present study, this rate is higher than the average rate reported in the literature for pT2 stages (16 and 9%, respectively) but similar for pT3 (40 and 37%, respectively).²⁹

In the present study, the nerve-sparing procedure was the only significant predictive factor (protective) of complications in univariate and multivariable analysis. Other factors related to patient characteristics, such as BMI,¹⁴ comorbidities,¹⁷ prostate volume,¹⁵ or cancer characteristics (such as prostate-specific antigen)¹⁷ have been reported to predict the risk of complications; these have not been confirmed in our series.

In clinical practice it is not possible (and not ethical) to assess the relationship between surgical volume and complications through a prospective, randomized study, that is, to randomly assign patients between centers at different volumes. Investigations on this topic are consequently of observational nature. Unlike many retrospective studies reported in the literature, the present study is prospective. Complications were collected and described in accordance with the recommended criteria of standardization. Data accuracy makes it possible to use the results obtained as measures of internal and external quality control and as a realistic tool for counselling patients who are candidates for RARP.

This study has several limitations. The analysis is focused on perioperative data; functional (urinary continence and erectile dysfunction) and long-term oncological results were not reported. Surgeon volume, shown to be a predictor of short-term perioperative complications,^{15,26} cannot be evaluated. Finally, caution must be used in comparing the results to other centers of equal volume, due to differences in patient characteristics, experience of surgeons, and postoperative protocols used.

Conclusions

Our study showed the perioperative results of RARP performed in a regional center of medium volume. The complication rate is similar to those reported by other high-volume European centers using the same standardized data-collection tools. This data suggests that inverse correlation between hospital volume and perioperative complication rate may not be significant when considering centers of high- and medium-volume. In this series, the nerve-sparing technique was found to be a predictor of postoperative complications at multivariable analysis. Further studies are needed to confirm these results.

Competing interests: The authors report no competing personal or financial interests related to this work.

This paper has been peer-reviewed.

References

- Pilecki MA, McGuire BB, Jain U, et al. National multi-institutional comparison of 30-day postoperative complication and readmission rates between open retropubic radical prostatectomy and robot-assisted laparoscopic prostatectomy using NSQIP. J Endourol 2014;28:430-6. https://doi.org/10.1089/ end.2013.0656
- Wallerstedt A, Tyritzis SI, Thorsteinsdottir T, et al. LAPPRO steering committee. Short-term results after robot-assisted laparoscopic radical prostatectomy compared to open radical prostatectomy. *Eur Urol* 2015;67:660-70. https://doi.org/10.1016/j.eururo.2014.09.036
- Yu H, Hevelone ND, Lipsitz SR, et al. Hospital volume, utilization, costs, and outcomes of robotassisted laparoscopic radical prostatectomy. J Urol 2012;187:1632-8. https://doi.org/10.1016/j. juro.2011.12.071
- Leow JJ, Leong EK, Serrell EC, et al. Systematic review of the volume-outcome relationship for radical prostatectomy. *Eur Urol Focus* 2018:4:775-89. https://doi.org/10.1016/j.euf.2017.03.008
- Sammon JD, Karakiewicz PI, Sun M, et al. Robot-assisted versus open radical prostatectomy: The differential effect of regionalization, procedure volume, and operative approach. J Urol 2013;189:1289-94. https://doi.org/10.1016/j.juro.2012.10.028
- Cooper MA, Ibrahim A, Lyu H, et al. Underreporting of robotic surgery complications. J Healthc Qual 2015;37:133-8. https://doi.org/10.1111/jhq.12036

- Menon M, Tewari A, Peabody J. Vattikuti Institute prostatectomy: Technique. J Urol 2003;169:2289-92. https://doi.org/10.1097/01.ju.0000067464.53313.dd
- Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000–2005. Urology 2007;69:1095-1101. https://doi.org/10.1016/j.urology.2007.03.042
- ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. *Mod Pathol* 2011;24:1-57. https://doi. org/10.1038/modpathol.2010.159
- Martin RC, Brennan MF, Jaques DP. Quality of complication reporting in the surgical literature. Ann Surg 2002;23:803-13. https://doi.org/10.1097/00000658-200206000-00007
- Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients. *Ann Surg* 2004;240:205-13. https://doi.org/10.1097/01. sla.0000133083.54934.ae
- Trinh QD, Bjartell A, Freedland SJ, et al. A systematic review of the volume-outcome relationship for radical prostatectomy. *Eur Urol* 2013;64:786-98. https://doi.org/10.1016/j.eururo.2013.04.012
- Trinh QD, Sammon J, Sun M, et al. Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: Results from the nationwide inpatient sample. *Eur Urol* 2012;61:679-85. https://doi.org/10.1016/j.eururo.2011.12.027
- Liu JJ, Maxwell BG, Panousis P, et al. Perioperative outcomes for laparoscopic and robotic compared with open prostatectomy using the national surgical quality improvement program (NSQIP) database. Urology 2013;82:579-83. https://doi.org/10.1016/j.urology.2013.03.080
- Novara G, Ficarra V, D'Elia C et al. Prospective evaluation with standardized criteria for postoperative complications after robotic-assisted laparoscopic radical prostatectomy. *Eur Urol* 2010;57:363-70. https://doi.org/10.1016/j.eururo.2009.11.032
- Coelho RF, Palmer KJ, Rocco B, et al. Early complication rates in a single-surgeon series of 2500 roboticassisted radical prostatectomies: Report applying a standardized grading system. *Eur Urol* 2010;57:945-52. https://doi.org/10.1016/j.eururo.2010.02.001
- Agarwal PK, Sammon J, Bhandari A, et al. Safety profile of robot-assisted radical prostatectomy: A standardized report of complications in 3317 patients. *Eur Urol* 2011;59:684-98. https://doi.org/10.1016/j. eururo.2011.01.045
- Rozet F, Jaffe J, Braud G, et al. A direct comparison of robotic assisted vs. pure laparoscopic radical prostatectomy: A single-institution experience. J Urol 2007;178:478-82. https://doi.org/10.1016/j. juro.2007.03.111
- Ploussard G, Xylinas E, Salomon L, et al. Robot-assisted extraperitoneal laparoscopic radical prostatectomy: Experience in a high-volume laparoscopy reference center. *BJU Int* 2010;105:1155- 60. https://doi.org/10.1111/j.1464-410X.2009.09013.x
- Carlsson S, Nilsson AE, Schumacher MC, et al. Surgery-related complications in 1253 robot-assisted and 485 open retropubic radical prostatectomies at the Karolinska University Hospital, Sweden. Urology 2010;75:1092-7. https://doi.org/10.1016/j.urology.2009.09.075
- Fischer B, Engel N, Fehr JL, et al. Complications of robotic assisted radical prostatectomy. World J Urol 2008;26:595-602. https://doi.org/10.1007/s00345-008-0287-7
- Lebeau T, Rouprêt M, Ferhi K, et al. Assessing the complications of laparoscopic robot-assisted surgery: the case of radical prostatectomy. *Surg Endosc* 2011;25:536-42. https://doi.org/10.1007/s00464-010-1210-z
- Tasci AI, Tufek I, Gumus E, et al. Oncologic results, functional outcomes, and complication rates of roboticassisted radical prostatectomy: Multicenter experience in Turkey including 1499 patients. World J Urol 2015;33:1095-102. https://doi.org/10.1007/s00345-014-1393-3
- Di Pierro GB, Grande P, Mordasini L, et al. Safety and efficacy of robot-assisted radical prostatectomy in a low-volume center: A 6-year, single-surgeon experience. *Anticancer Res* 2016;36:4201-7.
- Hu JC, Gold KF, Pashos CL, et al. Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol 2003;21:401-5. https://doi.org/10.1200/JC0.2003.05.169
- Budäus L, Sun M, Abdollah F, et al. Impact of surgical experience on in-hospital complication rates in patients undergoing minimally invasive prostatectomy: A population-based study. *Ann Surg Oncol* 2011;18:839-47. https://doi.org/10.1245/s10434-010-1300-0
- Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002;346:1138-44. https://doi.org/10.1056/NEJMsa011788
- Alibhai SMH, Leach M, Tomlinson G. Impact of hospital and surgeon volume on mortality and complications after prostatectomy. J Urol 2008;180:155-62. https://doi.org/10.1016/j.juro.2008.03.040
- Novara G, Ficarra V, Mocellin S, et al. Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. *Eur Urol* 2012;62:382-404. https://doi.org/10.1016/j.eururo.2012.05.047

Correspondence: Dr. Matteo Ferrari, Bellinzona Regional Hospital, Bellinzona, Switzerland; matteo.ferrari@eoc.ch